Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters

被引:8
|
作者
Takai, Shinji [1 ]
Jin, Denan
Inagaki, Sachiko
Yamamoto, Daisuke
Tanaka, Kazuhiko
Miyazaki, Mizuo
机构
[1] Osaka Med Coll, Dept Pharmacol, Takatsuki, Osaka 5898686, Japan
[2] Osaka Univ Pharmaceut Sci, Dept Clin Pharmacol & Pharmacokinet, Takatsuki, Osaka 5691094, Japan
[3] Osaka Med Coll, Biomed Computat Ctr, Takatsuki, Osaka 5898686, Japan
关键词
cardiac dysfunction; inhibitor; myocardial infarction; matrix metalloproteinase; left-ventricular dilatation;
D O I
10.1016/j.ejphar.2007.07.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Matrix metalloproteinase-9 activity is dramatically increased during the acute phase after myocardial infarction. However, the relationship between matrix metalloproteinase-9 activity and cardiac dysfunction is unclear. In 1-day post-myocardial infarction hamsters, matrix metalloproteinase-9 activity was significantly increased, while matrix metalloproteinase-2 activity was not increased. A selective matrix metalloproteinase inhibitor, [2S,4S]-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-[4-phenoxybenzoyl] aminopentanamide (ONO-4817), significantly suppressed matrix metalloproteinase-9 activity I day after myocardial infarction. ONO-4817 also significantly prevented the development of cardiac dysfunction and left-ventricular dilatation. Matrix metalloproteinase-9 might play a crucial role in cardiac dysfunction and left-ventricular dilatation during the very acute phase after myocardial infarction. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 50 条
  • [31] The Circular Relationship Between Matrix Metalloproteinase-9 and Inflammation Following Myocardial Infarction
    Deleon-Pennell, Kristine Y.
    Altara, Raffaele
    Yabluchanskiy, Andriy
    Modesti, Alessandra
    Lindsey, Merry L.
    IUBMB LIFE, 2015, 67 (08) : 611 - 618
  • [32] Chymase Inhibition Reduces Infarction and Matrix Metalloproteinase-9 Activation and Attenuates Inflammation and Fibrosis after Acute Myocardial Ischemia/Reperfusion
    Oyamada, Shizu
    Bianchi, Cesario
    Takai, Shinji
    Chu, Louis M.
    Sellke, Frank W.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (01): : 143 - 151
  • [33] Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
    Guzel, Savas
    Serin, Ozden
    Guzel, Eda Celik
    Buyuk, Banu
    Yilmaz, Guzin
    Guvenen, Guvenc
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2013, 28 (02): : 165 - 173
  • [34] Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction possible role in the development of cardiac rupture
    Kameda, Kunihiko
    Matsunaga, Toshiro
    Abe, Naoki
    Fujiwara, Takayuki
    Hanada, Hiroyuki
    Fukui, Kozo
    Fukuda, Ikuo
    Osanai, Tomohiro
    Okumura, Ken
    CIRCULATION JOURNAL, 2006, 70 (06) : 673 - 678
  • [35] Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction
    Kelly, Dominic
    Khan, Sohail Q.
    Thompson, Matt
    Cockerill, Gillian
    Ng, Leong L.
    Samani, Nilesh
    Squire, Iain B.
    EUROPEAN HEART JOURNAL, 2008, 29 (17) : 2116 - 2124
  • [36] Expression of serum matrix metalloproteinase-2 and plasma matrix metalloproteinase-9 in patients with acute myocardial infarction who underwent successful reperfusion
    Nakaya, R
    Lee, JD
    Shimizu, H
    Nakano, A
    Mitsuke, Y
    Yamazaki, T
    Ueda, T
    CIRCULATION, 2002, 106 (19) : 528 - 528
  • [37] Ginkgolide A alleviates cardiac remodeling in mice with myocardial infarction via binding to matrix metalloproteinase-9 to attenuate inflammation
    Zhao, Kun
    Li, Yong
    Zhou, Zihao
    Mao, Yukang
    Wu, Xiaoguang
    Hua, Dongxu
    Yong, Yonghong
    Li, Peng
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 923
  • [38] Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction
    Li Sai
    Zhang YanQiu
    Cui DongMei
    Li YinJun
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (03) : 625 - 630
  • [39] Matrix metalloproteinase 9 polymorphism and outcome after myocardial infarction
    Rodius, Sophie
    Mulliert, Guillermo
    Azuaje, Francisco
    Devaux, Yvan
    Wagner, Daniel R.
    CARDIOGENETICS, 2011, 1 (01) : 13 - 19
  • [40] Matrix Metalloproteinase-9 Production following Cardiopulmonary Bypass Was Not Associated with Pulmonary Dysfunction after Cardiac Surgery
    Lin, Tso-Chou
    Lin, Feng-Yen
    Lin, Yi-Wen
    Hsu, Che-Hao
    Huang, Go-Shine
    Wu, Zhi-Fu
    Tsai, Yi-Ting
    Lin, Chih-Yuan
    Li, Chi-Yuan
    Tsai, Chien-Sung
    MEDIATORS OF INFLAMMATION, 2015, 2015